Literature DB >> 9705598

Azathioprine in inflammatory bowel disease, a safe alternative?

A A Tanis1.   

Abstract

Azathioprine and its metabolite 6-mercaptopurine are effective in the treatment of inflammatory bowel disease. They are mostly used for reduction of the use of steroids, maintenance therapy after remission induction by cyclosporin and treatment of fistulae in Crohn's disease. Adverse effects occur in about 15% of patients. The main side effects are pancreatitis, allergic reactions, fever and bone marrow suppression. Symptoms, management and prevention are discussed. A blood monitoring schedule is suggested. Azathioprine and 6-mercaptopurine seem to be safe in pregnancy. There may be a slight increased risk for developing a non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705598      PMCID: PMC1781843          DOI: 10.1080/09629359891045

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  15 in total

1.  Pellagra, azathioprine and inflammatory bowel disease.

Authors:  P Jarrett; M Duffill; A Oakley; A Smith
Journal:  Clin Exp Dermatol       Date:  1997-01       Impact factor: 3.470

Review 2.  Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility.

Authors:  R Roubenoff; J Hoyt; M Petri; M C Hochberg; D B Hellmann
Journal:  Semin Arthritis Rheum       Date:  1988-11       Impact factor: 5.532

3.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.

Authors:  D H Present; S J Meltzer; M P Krumholz; A Wolke; B I Korelitz
Journal:  Ann Intern Med       Date:  1989-10-15       Impact factor: 25.391

4.  Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment.

Authors:  L J Kinlen
Journal:  Am J Med       Date:  1985-01-21       Impact factor: 4.965

5.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.

Authors:  W R Connell; M A Kamm; J K Ritchie; J E Lennard-Jones
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

6.  Safety of azathioprine in pregnancy in inflammatory bowel disease.

Authors:  E M Alstead; J K Ritchie; J E Lennard-Jones; M J Farthing; M L Clark
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

Review 7.  Azathioprine hypersensitivity-like reactions--a case report and a review of the literature.

Authors:  S R Knowles; A K Gupta; N H Shear; D Sauder
Journal:  Clin Exp Dermatol       Date:  1995-07       Impact factor: 3.470

8.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Authors:  W R Connell; M A Kamm; M Dickson; A M Balkwill; J K Ritchie; J E Lennard-Jones
Journal:  Lancet       Date:  1994-05-21       Impact factor: 79.321

9.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.

Authors:  D C Pearson; G R May; G H Fick; L R Sutherland
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

10.  An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease.

Authors:  W J Sandborn; E C Van O; B J Zins; W J Tremaine; D C Mays; J J Lipsky
Journal:  Gastroenterology       Date:  1995-12       Impact factor: 22.682

View more
  6 in total

1.  Ulcerative colitis: current treatment strategies and future prospects.

Authors:  Sagar Garud; Mark A Peppercorn
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

2.  Current use of immunosuppressive agents in inflammatory bowel disease patients in East China.

Authors:  Li-Juan Huang; Qin Zhu; Min Lei; Qian Cao
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

3.  Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance.

Authors:  Mi Sung Park; Dong Hyun Kim; Duk Hwan Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2014-09-20       Impact factor: 3.199

4.  Quality of care for patients with inflammatory bowel disease in East China.

Authors:  Qin Zhu; Qian Cao; Jian-Min Si
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

5.  Photodegradation of Azathioprine in the Presence of Sodium Thiosulfate.

Authors:  N'ghaya Toulbe; Ion Smaranda; Catalin Negrila; Cristina Bartha; Corina M Manta; Mihaela Baibarac
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

6.  NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases.

Authors:  Toshiyuki Sato; Tetsuya Takagawa; Yoichi Kakuta; Akihiro Nishio; Mikio Kawai; Koji Kamikozuru; Yoko Yokoyama; Yuko Kita; Takako Miyazaki; Masaki Iimuro; Nobuyuki Hida; Kazutoshi Hori; Hiroki Ikeuchi; Shiro Nakamura
Journal:  Intest Res       Date:  2017-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.